Cadila Healthcare shares slump over 4 per cent; m-cap down Rs 960 crore
Shares of Cadila Healthcare dropped over 4% amid media reports that the USFDA has expressed concerns over the manufacturing process
By PTI | Updated:
MUMBAI: Shares of Cadila Healthcare dropped over 4 per cent today amid media reports that the USFDA has expressed concerns over the manufacturing process at one of the company's facility.
The drug firm's scrip ended with a loss of 4.02 per cent at Rs 1,118.55 on the BSE. During the day, it tumbled 10 per cent to Rs 1,048.
At the NSE, the stock was down 4.12 per cent at Rs 1,120.10.
Led by the dip in the stock, the company's market value fell by Rs 959.85 crore to Rs 22,902.15 crore.
As per media reports, the US Food and Drug Administration (USFDA) has expressed concerns over the manufacturing process of at least one product at the drugmaker's Moraiya facility in Gujarat.
The USFDA reportedly communicated its concern to Cadila Healthcare in a Form 483, it said.
The drug firm's scrip ended with a loss of 4.02 per cent at Rs 1,118.55 on the BSE. During the day, it tumbled 10 per cent to Rs 1,048.
At the NSE, the stock was down 4.12 per cent at Rs 1,120.10.
Led by the dip in the stock, the company's market value fell by Rs 959.85 crore to Rs 22,902.15 crore.
As per media reports, the US Food and Drug Administration (USFDA) has expressed concerns over the manufacturing process of at least one product at the drugmaker's Moraiya facility in Gujarat.
The USFDA reportedly communicated its concern to Cadila Healthcare in a Form 483, it said.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
